Monday, 26 Jun 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
13 Nov 2016 News Two New Biologics for Polyarticular JIA
02 Nov 2016 News Decreased CD4 T Cells with Rituximab Infusions
22 Oct 2016 Social SURPRISE study 223 RA MTX-IR pts Rx w/ TCZ+MTX or TCZ- earlier DAS28 Resp & less Xray damage w/ addon vs switch Rx. https://t.co/HCsbfjdqtH
17 Oct 2016 Slide of the day New Biosimilars 2016: Many Indications Based on Few RCTs
13 Oct 2016 Social Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
10 Oct 2016 Social Phase II ACCLAIM small trial fails to show significant benefit/safety of Abatacept in Multiple sclerosis (42 pts) https://t.co/GeU5XnhePt
06 Oct 2016 News Biosimilar Reports – October 2016
04 Oct 2016 News Pharma Points Blame at PBMs
02 Oct 2016 News BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection
02 Oct 2016 Social Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/iYAzWwsyi2
29 Sep 2016 Social Humira and Xeljanz have equal outcomes in patient reported outcomes of efficacy in 12 mos ORAL study. https://t.co/RTcTOenN54
28 Sep 2016 Social Yale study of Alopecia (areata or universalis) showed 32% of 66pts improved with tofacitinib 5mg bid after 3 months. https://t.co/DBmnWEujiM
27 Sep 2016 News Ilaris Gets FDA Approval for Rare Febrile Disorders
26 Sep 2016 News FDA Approves Stelara for Crohn's Colitis
23 Sep 2016 News Restricting High Price Drugs - A Dangerous Trend?
20 Sep 2016 Social JIA Uveitis refractory to MTX, DMARDs, TNFi, successfully Rx in 10/17 w/ Tocilizumab after 5.7 mos,7 steroid sparing https://t.co/eDoX3w5g7L
20 Sep 2016 News After the 1st TNF Inhibitor, a Non-TNF Biologic is Next Best
14 Sep 2016 Social RTX biosimilar CT-P10 comparable to rituximab in efficacy, pharmacodynamics, & immunogenicity/safety. @DrPetryna https://t.co/hNjcxbF9Mu
14 Sep 2016 Social TNFi induced Psoriasis can be treated w/ TNFi D/C, another TNFi (48-85% recurrence) or Stelara. Good short review https://t.co/PAtJOOfFIV
07 Sep 2016 News Is Biologic Safety Different in the Elderly?